- Home
- RM vs NNNN Comparison
RM vs NNNN Comparison
Compare RM & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- NNNN
- Stock Information
- Founded
- RM 1987
- NNNN 2021
- Country
- RM United States
- NNNN Germany
- Employees
- RM N/A
- NNNN N/A
- Industry
- RM Finance: Consumer Services
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RM Finance
- NNNN Health Care
- Exchange
- RM Nasdaq
- NNNN Nasdaq
- Market Cap
- RM 298.3M
- NNNN 267.7M
- IPO Year
- RM 2012
- NNNN 2025
- Fundamental
- Price
- RM $28.89
- NNNN $6.43
- Analyst Decision
- RM Hold
- NNNN
- Analyst Count
- RM 3
- NNNN 0
- Target Price
- RM $30.00
- NNNN N/A
- AVG Volume (30 Days)
- RM 47.5K
- NNNN 28.8K
- Earning Date
- RM 04-30-2025
- NNNN 01-01-0001
- Dividend Yield
- RM 4.15%
- NNNN N/A
- EPS Growth
- RM 41.13
- NNNN N/A
- EPS
- RM 3.29
- NNNN 0.06
- Revenue
- RM $577,647,000.00
- NNNN $8,185,146.00
- Revenue This Year
- RM $14.45
- NNNN N/A
- Revenue Next Year
- RM $8.95
- NNNN N/A
- P/E Ratio
- RM $8.77
- NNNN $118.17
- Revenue Growth
- RM 6.45
- NNNN 21.95
- 52 Week Low
- RM $25.41
- NNNN $5.18
- 52 Week High
- RM $37.52
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- RM 41.75
- NNNN N/A
- Support Level
- RM $26.18
- NNNN N/A
- Resistance Level
- RM $29.48
- NNNN N/A
- Average True Range (ATR)
- RM 1.46
- NNNN 0.00
- MACD
- RM -0.35
- NNNN 0.00
- Stochastic Oscillator
- RM 34.28
- NNNN 0.00
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.